Study Design, Setting, and Participants
neurological disease, osteoporosis-related fractures, cognitive impairment, fracture, Parkinson or multiple sclerosis, osteoporosis
NEUROLOGICAL DISEASE, OSTEOPOROSIS
This assessor-blinded, parallel-group (1:1 ratio) RCT was conducted between March 2021 and December 2022 at a laboratory in Aalborg University in Denmark. The trial protocol was approved by the North Denmark Region Committee on Health Research Ethics and the Danish Data Protection Agency. All participants provided written informed consent. The trial protocol (Individuals were recruited through radio and television advertisements and snowball sampling from March through November 2021. Eligible individuals were 65 years or older, community dwelling, and able to walk without a walking aid. Individuals were excluded if they (1) had any of the following self-reported conditions: orthopedic surgery within the past 12 months, osteoporosis or osteoporosis-related fractures (low-impact hip, spine, or wrist fracture), or progressive neurological disease (eg, Parkinson or multiple sclerosis); (2) had an unstable medical condition that prevented safe participation; (3) had a severe cognitive impairment (score <8 in the Short Orientation-Memory-Concentration Test); or (4) were currently participating in another fall prevention trial.